Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ABL1 |
Variant | E279K |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ABL1 E279K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E279K has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 21562040, PMID: 16754879), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Apr 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
ABL1 mutant ABL1 E279K |
Transcript | NM_005157.6 |
gDNA | chr9:g.130872141G>A |
cDNA | c.835G>A |
Protein | p.E279K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_005157.6 | chr9:g.130872141G>A | c.835G>A | p.E279K | RefSeq | GRCh38/hg38 |
NM_005157.5 | chr9:g.130872141G>A | c.835G>A | p.E279K | RefSeq | GRCh38/hg38 |
NM_005157 | chr9:g.130872141G>A | c.835G>A | p.E279K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|